The following variables were found to be significantly associated with CKD progression: ethnicity (χ2 = 66.7, p < 0.001), polyclinic seen (χ2 = 76.4, p < 0.001), smoking status (χ2 = 8.64, p = 0.011), baseline CKD (χ2 = 147.8, p < 0.001) and albuminuria stage (χ2 = 668.9, p < 0.001), presence of diabetes (χ2 = 165.0, p < 0.001), hypertension (χ2 = 23.2, p < 0.001) and hyperlipidemia (χ2 = 26.9, p < 0.001) at baseline, use of ACE inhibitors/ARBs at baseline (χ2 = 155.0, p < 0.001), ever used SGLT2i (χ2 = 32.2, p < 0.001), and ever been counseled for CKD (χ2 = 119.6, p < 0.001). The gene discussed is ACE; the disease is hyperlipidemia.